Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case

Reuters12-05

Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case

By Blake Brittain

Dec 5 (Reuters) - Medical device maker Insulet PODD.O convinced a jury that Korean rival EOFlow 294090.KQ owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in Massachusetts federal court on Thursday.

The jury in its verdict on Tuesday agreed with Insulet that EOFlow stole the Acton, Massachusetts-based company's secrets in order to create a competitor to Insulet's Omnipod, a wearable insulin pump for diabetes patients.

Spokespeople for EOFlow did not immediately respond to a request for comment on the verdict. Insulet president Jim Hollingshead said the company was "extremely pleased" with the verdict.

EOFlow stock was down nearly 30% at the close of Thursday trading on Korea's stock market.

Insulet sued EOFlow last year. Its lawsuit said EOFlow hired away former Insulet employees to develop its EOPatch, an insulin device similar to Insulet's Omnipod.

After failing for six years to design its own patch pump, the lawsuit said EOFlow began selling a "completely redesigned" EOPatch that was "strikingly similar" to the Omnipod less than two years after taking advantage of the former Insulet employees' confidential knowledge.

EOFlow denied the allegations.

Medtronic MDT.N announced last May that it would acquire EOFlow but canceled the deal last December, citing "multiple breaches" of their agreements.

(Reporting by Blake Brittain in Washington; Editing by Bill Berkrot)

((blake.brittain@tr.com; +1 (202) 938-5713))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489846938?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-05 23:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489846938","market":"us","top_or_hot":-1,"title":"Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case</title></head><body><p>By Blake Brittain</p><p>\n<span>Dec 5 (Reuters)</span><span> - </span>Medical device maker Insulet <span>PODD.O</span> convinced a jury that Korean rival EOFlow <span>294090.KQ</span> owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in Massachusetts federal court on Thursday.</p><p>The jury in its verdict on Tuesday agreed with Insulet that EOFlow stole the Acton, Massachusetts-based company's secrets in order to create a competitor to Insulet's Omnipod, a wearable insulin pump for diabetes patients.</p><p>Spokespeople for EOFlow did not immediately respond to a request for comment on the verdict. Insulet president Jim Hollingshead said the company was \"extremely pleased\" with the verdict.</p><p>EOFlow stock was down nearly 30% at the close of Thursday trading on Korea's stock market.</p><p>Insulet sued EOFlow last year. Its lawsuit said EOFlow hired away former Insulet employees to develop its EOPatch, an insulin device similar to Insulet's Omnipod.</p><p>After failing for six years to design its own patch pump, the lawsuit said EOFlow began selling a \"completely redesigned\" EOPatch that was \"strikingly similar\" to the Omnipod less than two years after taking advantage of the former Insulet employees' confidential knowledge.</p><p>EOFlow denied the allegations.</p><p>Medtronic <span>MDT.N</span> <span>announced last May</span> that it would acquire EOFlow but canceled the deal last December, citing \"multiple breaches\" of their agreements. </p><p> (Reporting by Blake Brittain in Washington; Editing by Bill Berkrot)</p><p> ((blake.brittain@tr.com; +1 (202) 938-5713))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsulet wins $452 mln US verdict against EOFlow in insulin pump secrets case\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-05 23:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nL6N3N60I2:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets caseBy Blake Brittain\nDec 5 (Reuters) - Medical device maker Insulet PODD.O convinced a jury that Korean rival EOFlow 294090.KQ ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nL6N3N60I2:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0211331839.USD","symbol_name":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nL6N3N60I2:1","article_id":"2489846938","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489846938","pubTimestamp":1733414374,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets caseBy Blake Brittain Dec 5 (Reuters) - Medical device maker Insulet PODD.O convinced a jury that Korean rival EOFlow 294090.KQ ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","BK4585":"ETF&股票定投概念","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","PODD":"银休特","BK4082":"医疗保健设备","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","BK4588":"碎股","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK4551":"寇图资本持仓","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","MDT":"美敦力","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC"},"translate_title":"Insulet在胰岛素泵秘密案中赢得美国对EOFlow的4.52亿美元判决","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PODD":0.9,"MDT":0.9},"content_text":"Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets caseBy Blake Brittain\nDec 5 (Reuters) - Medical device maker Insulet PODD.O convinced a jury that Korean rival EOFlow 294090.KQ owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in Massachusetts federal court on Thursday.The jury in its verdict on Tuesday agreed with Insulet that EOFlow stole the Acton, Massachusetts-based company's secrets in order to create a competitor to Insulet's Omnipod, a wearable insulin pump for diabetes patients.Spokespeople for EOFlow did not immediately respond to a request for comment on the verdict. Insulet president Jim Hollingshead said the company was \"extremely pleased\" with the verdict.EOFlow stock was down nearly 30% at the close of Thursday trading on Korea's stock market.Insulet sued EOFlow last year. Its lawsuit said EOFlow hired away former Insulet employees to develop its EOPatch, an insulin device similar to Insulet's Omnipod.After failing for six years to design its own patch pump, the lawsuit said EOFlow began selling a \"completely redesigned\" EOPatch that was \"strikingly similar\" to the Omnipod less than two years after taking advantage of the former Insulet employees' confidential knowledge.EOFlow denied the allegations.Medtronic MDT.N announced last May that it would acquire EOFlow but canceled the deal last December, citing \"multiple breaches\" of their agreements.  (Reporting by Blake Brittain in Washington; Editing by Bill Berkrot) ((blake.brittain@tr.com; +1 (202) 938-5713))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489846938"}